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The provision of dynamic splicing events constitutes the reﬂected nature of neoplasia that locally inﬁltrates and systemically
spreads in terms of evolutionary attributes of the primary and various secondary pathways in malignant transformation. The
signiﬁcant diversity in molecular characterization of the given tumor lesion would adaptively conform to dynamics of splicing as
enhanced or silenced exons of the premessenger RNA molecule. The proteins synthesized are in turn potential modiﬁers in further
gene expression within such contexts as RNA:protein and RNA:DNA binding events. The recognition of pathways of incremental
scope would underline the development of lesions, such as tumors, as multiple alternative splicing phenomena primarily aﬀecting
molecular physicochemical identity. It is within contexts of operative intervention and modiﬁcation that the real identity of the
malignant neoplastic process arises, within terms of reference of contextual splicing events. Disrupted gene expression is thus a
referential pathway in the modiﬁcation of splicing that may prove constitutive or alternative, in ﬁrst instance, but also aberrant as
the lesion progresses locally and systemically.
1.Introduction
Gene expression proﬁles and their regulation illustrates
additional layers in regulatory control of protein synthesis
that implicate especially the relatively important roles of
constitutiveandalternativesplicingofexonsofpremessenger
RNA.
The spliceosome machinery, in particular, would con-
stitute an expressive mechanism in the further evolution of
splicing enhancement or silencing [1]. It is the absence of
mutations in many disease entities, such as those charac-
terized by tau neuroﬁbrillary tangle formation, that would
indicate a central role, in disease, for alternative splicing
and for the aberrant role of alternative exons in pre-mRNA
synthesis.
The overall dimensions of regulation of selection would
concerninparticulartheexclusionofvariousexonsandnon-
coding introns in the subsequent generation of messenger
RNA transcripts and novel or alternative isoforms of the
protein molecule. Diﬀerential splicing can now be studied
genomewide using whole-transcript microarrays [2].
2. Variabilityin GeneExpression
The variability, thus created, in subcellular localization, in
enzymatic activity, and particularly in degrees of stability of
protein molecules, renders alternative splicing a source for
diversity in cellular functionality and viability.
Disease entities arise in terms of such protein diversity
engendered by extensive exon splicing, in further enhancing
diﬀerential expression of individual genes. The combinato-
rialnatureofregulationofalternativesplicingisconsiderable
and would call into operation both transregulatory splicing
factors and cis-acting elements within the sequence structure
of the pre-mRNA molecule. The organization of the exon-
exon junction complex provides a link between biogenesis,
nuclear export, and translation of the transcripts [3].
A basic concept of homeostatic equilibrium would
characterize systems of evolution implicating such processes
as phosphorylation of serine- and arginine-rich proteins that
act as transfactors in alternative splicing.
The absence or presence of mutations that may be, at
times, related to aberrant splicing patterns would indicate2 Pathology Research International
a mechanistic framework in further enhancing cellular
diversity, linked closely to genomic regulation.
3. ExpressionComplexity
The complexity in gene expression appears to promote
the important roles for splicing of pre-mRNA molecules
in a manner that is illustrative of the potentially huge
diversity at the level of RNA transcription. Transcriptional
coupling to alternative splicing is a key feature of the DNA-
damage response [4]. Translational and posttranslational
modiﬁcations of protein structure are further mechanisms
in the development of adaptive change in response to
evolutionary need. Protein phosphorylation, in particular,
appears implicated in the silencing of serine- and arginine-
rich proteins as transfactors and might signiﬁcantly promote
exon exclusion from the pre-mRNA molecule sequence.
The general ﬁrst principles in organization of exon
sequence splicing enhancement and silencing appear of
paramount importance in further elucidating the nature of
mechanistic pathways that operate in cancerous transforma-
tion and malignancy.
ThetransfactorsinaberrantsplicingofmRNAregulatein
terms also of the evolution of several potential biomarkers in
cancer. It would appear that the nature of protein diversity in
neoplastic lesions arises largely in terms of aberrant splicing
and often in the absence of correspondingly detectable
mutations. Aberrant splicing may initiate abnormal exon
skipping, intron retention or the introduction of new splice
sites [5].
However, mutations may at times aﬀect splicing sites and
the spliceosome subcomponents in further development of
engendered protein diversity [6].
Neoplastic transformation involving lesions such as
carcinomas of the prostate and breast would indicate
that protein diversity reﬂects the multimodal diversity in
gene expression arising through the generation of mRNA
isoforms, as these subsequently are transported between
nucleus and cytosol. The combinatorial mechanics of pro-
tein:RNA binding would at times interfere with RNA:DNA
binding in a manner further promoting exonic splicing
enhancement or silencing.
The potentiality for involvement in diseases such as
Duchenne muscular dystrophy and spinal muscular atrophy
is also reﬂected in inherited disorders such as cystic ﬁbrosis
and beta-thalassemia. Antisense-mediated exon skipping is
one of the most promising approaches for the treatment
of Duchenne muscular dystrophy and has recently been
shown to correct the reading frame and restore dystrophin
expression in vitro and in vivo [7].
4. CombinatorialRegulation
The general principles of such combinatorial control in
alternative splicing would arise as a derived parametric
functionality of the constitutive splicing patterns in the ﬁrst
instance.
5. AberrantSplicing
Aberrant splicing mechanics would secondarily alter the
gene expression of several protein synthetic pathways in
a manner predominantly correlative with the molecular
stability and the intracellular localization of the synthesized
protein molecules.
Referential indicators of the various roles of pathway
generation would also arise within contexts of progressively
active, aberrant splicing patterns.
Transposable elements are major sources of new exons in
higher eukaryotes [8].
Exon skipping, in particular, helps illustrate the added
roles of involvement by engendered nonsense mutations
and stop condons in inducing absence of the protein or
the production of a much truncated form of the molecule.
Dystrophin, in particular, appears especially susceptible
to the evolutionary modiﬁcation in protein expression,
as dimensionally expressed in terms either of Duchenne
muscular dystrophy or else as Becker’s muscular dystrophy.
Antisense oligosaccharides and the implied functionality
or dysfunctionality induced by small nuclear ribonucleopro-
tein and by small interfering RNA molecules would appear
examples of classic forms of inﬂuence that are potential
targets in control of alternative or aberrant splicing.
6. EmpiricControl of SplicingEvents
Empiric control of splicing, with the use of administered
small molecules, would indicate or earmark systems of
variability in expression of individual genes.
Transcriptome comparison has been limited to diﬀer-
ential analysis at the gene level instead of the individual
transcript isoform level [9].
Contextualmicroenvironmentalconditioningappearsan
essential operative series of systems in enhancing or silencing
both constitutive and alternative splicing.
Multiple tau isoforms, as splicing alternatives in neu-
roﬁbrillary tangle formation, would correlate with progres-
sion of dementia as seen with Alzheimer’s disease and
frontotemporal dementia, and also with various “tangle-
only” dementias such as Pick’s disease, corticobasal degener-
ation, progressive supranuclear palsy, and argyrophilic grain
disease. Restricted tau isoform expression is related to a
hyperphosphorylation of the tau molecule.
Microtubular assembly is impaired as a consequence
of neuroﬁbrillary tangle formation in terms relative to the
emergence of other identiﬁable molecular species. Partly
aﬀected would appear to be the intraneuronal traﬃcking
systems as readily indicated by axonal pathology.
7.AggressiveNeoplasia
The emergence of aggressive forms of neoplasia is exempli-
ﬁed particularly by the androgen-independent forms of pro-
static adenocarcinoma that are progressively dediﬀerentiated
as a consequence of possible aberrant splicing of pre-mRNA
molecules. In terms of the added emergence of variably
expressed protein molecules, the neoplastic lesion indicatesPathology Research International 3
the malignant transformation step in further modiﬁcation of
gene expression via aberrant splicing.
Spinal muscular atrophy is remarkable in the human as
a consequence of the duplication of the survival of motor
neuron gene involvement in terms of the SMN2 with exon
7 exclusion.
With reference to the modiﬁcation of alternative splicing
resultsitwouldappearthattransfactorsoperateascontextual
conditioning parameters within a setting especially of con-
stitutive splicing. Indicators of the overall dimensions of the
splicing mechanisms aﬀecting the pre-mRNA would indicate
protein diversity as a multifunctional motif in further
enhancement or suppression of pathological endpathways
[10].
The balance of factors controlling apoptosis may impli-
cate Bcl isoforms, and their generation would characterize
in strict terms the evolutionary dynamics of such lesions as
neoplastic transformation and progression.
8.MalignantNeoplastic Change
Neoplastic malignant transformation appears to arise as a
phenomenon secondarily characterizing attributes of alter-
native, aberrant splicing. The lack of mutations in such cases
may presumably call into operation a serial modiﬁcation
of systems reﬂected as progression parameters, in tumor
dediﬀerentiation and spread.
Progression of neoplastic transformation appears linked
to a sequential promotion of various pathway eﬀects as illus-
trated by a tendency for tumor dediﬀerentiation, concurrent
with progression of spread of the neoplastic lesion. Methods
to analyze gene expression and identify regulatory elements
in BRCA 1/2 are now required to complement standard
approaches to mutational analysis [11].
Suppressor genes and oncogenes, in general, would
reﬂect the introduction of a series of modifying steps
that augment protein diversity as indicated by diagnostic
biomarkers of malignancy.
Spread of tumors is an incorporated system of mechanis-
tic pathways that alternatively modiﬁes gene expression, as
parallel steps to evolving neoplastic progression.
9. IncreasingProteinDiversity
Increasing splicing and increasing protein diversity, and pro-
teinmoleculartruncation,wouldfurtherevolveassystemsof
recognizable identity within contextual change, as primary
malignant transformation. An increasing proportion of
mutations is now believed to inﬂuence m RNA splicing [12].
Indeed, the terms of reference of alternative splicing
would arise within contexts of operatively constitutional
change and also as possibly aberrant gene expression.
Many alleles of human disease genes have mutations within
splicing consensus sequences that activate cryptic splice sites
[13]. Splicing further indicates the resolving dimensions of
neoplastic progression as an expression of the splicing of
diverse protein molecular species.
An example is the altered balance between Bcl-xL and
Bcl-xS, two splice variants of the apoptosis regulator Bcl-x
[14].
Combinatorial inﬂuence as systems of constitutive splic-
ing would arise as predominant exclusion of introns and
relative preservation of exons in splicing.
The engine in manufacturing modiﬁed protein diversity
indicates the constant operability of systems of change
in progression of a given malignant neoplasm, both as
a genetic lesion and also as a system of evolutionary
character and transformability. Certain p53 isoforms are
aberrantly expressed in various tumors strongly implying
their involvement in tumorigenic events [15].
The given dimensional series of events reﬂects the
real nature of the alternative, aberrant splicing mechan-
ics, beyond actual biochemical identity of the skipped or
included exon in question.
Diversity of acquired change in gene expression would
hence constitute a realization of events as active components
of the mechanistic splicing pathways.
Primary events in splicing are the true biochemical
expression of a transforming identity in cancerogenesis and
progression, both locally within the primary organ, and also
systemically within the body. Altered RNA binding proteins
appear to act as global generator of cancer-related RNA
alternative splicing [16].
A multievolutionary set of principles seems to govern
tumorprogressionintermsalsoofsuchsystemsasCD44that
acts prominently as cell adhesion pathways [17].
Stromal inﬁltration is, hence, the overall characterization
of a series of potential splicing events that contextually
incorporate alternative pathways, with aberrant systems of
progression as increasing protein diversity in molecular
synthesis.
Overall dimensions are the product of an involvement of
events that modiﬁes in sequential fashion the protein molec-
ular characterization arising as primary splicing events.
Operative intracellular traﬃcking and the formation of
intranuclear inclusions, and also the transport across the
nuclear membrane, are systems of operative intervention
and also secondary pathways leading to potentially diverse
splicing events aﬀecting messenger RNA.
The controlled expression of diverse isoforms of protein,
in turn, regulates or modiﬁes the expression of genes.
Protein:RNAinteractionandthemodiﬁcationsinRNA:DNA
binding would indicate the potentiality for progression of
lesions such as malignant neoplasms that adaptively induce
modiﬁcations in protein constitutive identity and in cellular-
matrix interactions such as those due to the local inﬁltration
of tissues.
10. Concluding Remarks
The lack of recognizable mutation in many instances of
alternative splicing creates an environment for diversity that
is reﬂected secondarily, and also quantitatively, in molecular
modiﬁcation.4 Pathology Research International
The physicochemical attributes in lesion creation indi-
cate a contextual diversity that is modiﬁable in terms of
neoplastic progression.
Hence, the primary nature of evolving neoplastic lesions
is further classiﬁable in terms of the attributes of the primary
or predominant splicing events.
Induced referential systems of such neoplastic change are
illustrative of the new attributes that sequentially promote
further aberrant splicing events, as dictated by evolutionary
progression of the lesion both locally and systemically.
Dimensions of involvement by splicing of exons, with
predilected deﬁnition of the exon-intron junctions, the lig-
ation of the individual exons, and the inclusion or exclusion
of exons, require a dynamic interactivity of cis-acting factors
and transregulatory factors.
The involvement implicates interactions of gene tran-
scriptional activity within a context of production of the pre-
mRNA as directly conducive to the speciﬁc exonic sequence
of the resultant messenger RNA transcript.
The inherent susceptibility of the exon/intron sequences
to splicing is implicated as a poorly understood parameter in
the overall phenomenon of splicing of premessenger RNA.
It would appear that turnover dynamics allow for the
permissive operation of both cis- and transfactors that
coherently incorporate constitutive and regulated splicing
in a manner that actually promotes alternative regulatory
splicing. In this sense, the spliceosome engine is a regulatory
mechanism in its own right that promotes further control at
multipleoperativelevelsintheexecutivedynamicsofsplicing
interventions.
In terms, therefore, of the systematic manipulative inter-
ventions of splicing, there might be introduced assembly of
the spliceosome that, in a speciﬁc manner, directly promotes
deterministic action of several transacting factors, as seen in
neoplastic evolution.
Clear-cut indicators of such transacting factors would
operate as a modulating series of pathways primarily impli-
cating cis-factors also. Inherent susceptibility of exonic and
intronic elements, to activation and, particularly, to inhibi-
tion, would operate as contextual sequences of enhancement
or silencing of the splicing events.
A primacy in the operability of the exonic and intronic
sequence silencing mechanisms would hence be contextually
relevant in terms of a sequence-manipulating series of
conditioning mechanics.
It is with reference to cis-factors, therefore, that constitu-
tive splicing would carry signiﬁcant power in the execution
of forms of splicing directly conducive to the production of
a ﬁnal messenger RNA transcript that translocates from the
nucleus to the cytoplasm. In this connection, the phosphory-
lation of protein components of the spliceosome, such as the
SR proteins, would indicate a further operative involvement
of other components of the spliceosome, particularly the
heterogeneous nuclear RNA, as transnuclear membrane
translocation.
Proteinphosphorylationis,hence,bothagenerallyappli-
cable modifying step in protein interactivity or reactivity
and also speciﬁc modulatory mechanisms in the localization
dynamics of the protein-RNA complex within the cell.
It is in terms of ongoing contextual setting of the
exonic and intronic silencing mechanics of splicing that the
main modulatory systems in splicing would contribute by
transfactors in tumor evolution and spread.
The marked diversity of protein molecular phenotype
is signiﬁcant in terms of such contextual sequences that
promote overall dynamics of turnover of protein molecules.
Both direct and also indirect posttranslational modiﬁcations
of protein molecules would implicate subsequent conse-
quences in molecular stability, enzymatic activity, and also
localization speciﬁcs within the cell.
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